{"slideshow_credits": null, "snippet": "The F.D.A. was right to suspend a leukemia drug while researchers try to identify which patients might be helped without serious risk of harm.", "abstract": "Editorial supports Food and Drug Administration's decision to suspend sales of Iclusig, promising leukemia drug that turned out to be unexpectedly dangerous; holds concerns about the decision disrupting treatment of patients who benefit from drug and can tolerate the side effects are unwarranted;  notes FDA has set up streamlined process for such patients to continue receiving treatment.", "section_name": "Opinion", "print_page": "28", "document_type": "article", "byline": {"person": [], "organization": "THE EDITORIAL BOARD", "original": "By THE EDITORIAL BOARD", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/11/06/opinion/approving-and-suspending-a-dangerous-drug.html", "lead_paragraph": "The F.D.A. was right to suspend a leukemia drug while researchers try to identify which patients might be helped without serious risk of harm.", "headline": {"main": "Approving, and Suspending, a Dangerous Drug", "print_headline": "Approving, and Suspending, a Dangerous Drug", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "52799e7e38f0d8267390887b", "word_count": "281", "multimedia": [], "pub_date": "2013-11-06T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"value": "Editorials", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Iclusig (Drug)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Leukemia", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "2"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}